Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classificação em ações #4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preço da ação
$27.18
Última sincronização: 2026-07-31
Valor de mercado
$3.38B
Variação (1 dia)
-1.41%
Variação (1 ano)
197.05%
País
US
Negociar Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
Histórico de rendimento de dividendos para Tango Therapeutics, Inc. (TNGX)
O rendimento de dividendos (TTM) da Tango Therapeutics, Inc. (símbolo da ação: TNGX) em 2023-12-31 é: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Tango Therapeutics, Inc. (TNGX) de 2019 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL